The selective serotonin reuptake inhibitor paroxetine fared better than fluoxetine and escitalopram in managing premature ejaculation (PE), demonstrating improved intravaginal ejaculatory latency time (IELT), according to a meta-analysis. Moreover, combining paroxetine with tadalafil or behavioural therapy was better than paroxetine alone in improving IELT.
Individuals with immunoglobulin A vasculitis (IgAV, otherwise known as Henoch-Schönlein purpura) – a type of small vessel vasculitis more common in children – have an increased risk of hypertension and chronic kidney disease (CKD), according to a retrospective analysis.
A recent study has shown the efficacy and safety of radio frequency ablation (RFA) in small renal masses, particularly those <3 cm in diameter, providing good oncologic outcomes at long-term follow-up.
It appears safe for men on active surveillance (AS) of localized prostate cancer to drink coffee moderately, suggests a recent study. However, this represents only an association and may differ in some patients, particularly those with slow caffeine metabolism.
Radical prostatectomy can provide long-term survival benefits and reduce the risk of distant metastasis in otherwise healthy men with clinically detected, localized prostate cancer, according to findings from 23 years of follow-up of the SPCG-4 study (Scandinavian Prostate Cancer Group Study Number 4).
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.